质子泵抑制治疗遗传性贫血继发性血色病:一项III期安慰剂对照随机交叉临床试验
这项III期随机安慰剂对照交叉试验纳入30例非输血依赖的遗传性贫血伴轻中度铁过载成人,比较埃索美拉唑40 mg每日两次与安慰剂各12个月对MRI肝铁含量的影响。埃索美拉唑使肝铁含量较安慰剂多降低0.55 mg Fe/g dw(95%CI 0.05至1.06;p=0.03),耐受良好。
要点
- 埃索美拉唑较安慰剂显著降低肝铁含量,差值0.55 mg Fe/g dw(95%CI 0.05–1.06;p=0.03)。
- 埃索美拉唑治疗前后肝铁含量平均变化-0.57(SD 1.20)vs 安慰剂-0.11 mg Fe/g dw(SD 0.75)。
- 不良事件均为轻度,无患者因副作用退出研究。
核心结论
- 在非输血依赖的遗传性贫血异质性患者群中,埃索美拉唑较安慰剂显著降低肝铁含量。
- 从国际视角看,质子泵抑制剂可能成为无法获得或不耐受铁螯合剂患者的唯一现实治疗选择。
研究设计与样本
- III期随机安慰剂对照交叉临床试验。
- 纳入30例非输血依赖的遗传性贫血伴轻中度铁过载成人。
- 埃索美拉唑40 mg每日两次或安慰剂治疗12个月。
- 主要终点为MRI测量的肝铁含量变化。
主要发现
- 埃索美拉唑治疗使肝铁含量较安慰剂多降低0.55 mg Fe/g dw(95%CI 0.05至1.06;p=0.03)。
- 埃索美拉唑起始时肝铁含量中位基线为4.99 mg Fe/g dw,安慰剂起始时为4.49 mg Fe/g dw。
- 埃索美拉唑治疗后肝铁含量平均变化为-0.57 mg Fe/g dw(SD 1.20),安慰剂治疗后为-0.11 mg Fe/g dw(SD 0.75)。
- 埃索美拉唑耐受良好,报告的不良事件均为轻度,无患者因副作用退出研究。
临床怎么用
- 作者认为,从国际视角看该结果可能对无法获得或不耐受铁螯合剂的许多患者有重大意义,质子泵抑制剂可能经常是唯一现实的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side-effects, high costs, and the lack of availability in many countries with a high prevalence of hereditary anemias. In this phase III randomized placebo-controlled trial, we assigned adults with non-transfusion-dependent hereditary anemias with mild-to-moderate iron overload to receive esomeprazole (at a dose of 40 mg twice daily) or placebo for 12 months in a cross-over design. The primary end point was change of liver iron content measured by MRI. A total of 30 participants were enrolled in the trial. Treatment with esomeprazole resulted in a statistically significant reduction in liver iron content that was 0.55 mg Fe/g dw larger than after treatment with placebo (95%CI [0.05 to 1.06]; p = 0.03). Median baseline liver iron content at the start of esomeprazole was 4.99 versus 4.49 mg Fe/g dw at start of placebo. Mean delta liver iron content after esomeprazole treatment was -0.57 (SD 1.20) versus -0.11 mg Fe/g dw (SD 0.75) after placebo treatment. Esomeprazole was well tolerated, reported adverse events were mild and none of the patients withdrew from the study due to side effects. In summary, esomeprazole resulted in a significant reduction in liver iron content when compared to placebo in a heterogeneous group of patients with non-transfusion-dependent hereditary anemias. From an international perspective this result can have major implications given the fact that proton pump inhibitors may frequently be the only realistic therapy for many patients without access to or not tolerating iron chelators.
引用
- van Vuren A, Kerkhoffs JL, Schols S, et al. Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial. Am J Hematol. 2022. PMID: 35472008. doi:10.1002/ajh.26581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。